Magmaris: the impact of scaffold design and materials on reducing thrombogenicity
|
|
- Brian Gaines
- 6 years ago
- Views:
Transcription
1 : the impact of scaffold design and materials on reducing thrombogenicity Michael Joner, MD Deutsches Herzzentrum München und Deutsches Zentrum für Herz-Kreislaufforschung e.v.
2 Potential conflicts of interest Speaker's name: Michael Joner I have the following potential conflicts of interest to report: Receipt of honoraria or consultation fees: Boston Scientific, Biotronik, OrbusNeich, Coramaze, Astra Zeneca, Bristol-Myers Squibb
3 Definite/Probable Scaffold Thrombosis (in %) Definite/Probable Scaffold Thrombosis (in %) Definite/Probable Scaffold Thrombosis (in %) Scaffold thrombosis in ABSORB BVS Recent studies show increased thrombosis tendency in BVS vs DES. Thrombosis in general however has multifactorial causes, thick strut design being one of them ABSORB II 3-year data 1 ABSORB III 2-year data 2 AIDA 2-year data 3 4.0% P= % P=NS 4.0% P< % 3.5% 3.5% 3.5% 3.0% 2.8% 3.0% 3.0% 2.5% 2.5% 2.5% 2.0% 2.0% 1.9% 2.0% 1.5% 1.5% 1.5% 1.0% 1.0% 0.8% 1.0% 0.9% 0.5% 0.5% 0.5% 0.0% Absorb 0.0% Xience 0.0% Absorb Xience 0.0% Absorb Xience 1) Adapted from Serruys P. et al., The Lancet 2016; 388(10059): ) Adapted from Ellis S.G.oral abstract presentation at ACC ) Adapted from Wykrzykowska J.J. et al., New England Journal of Medicine 2017, published online ahead of print
4 Scaffold thrombosis in DREAMS-1G BIOSOLVE-I 36-month follow-up Definite/Probable Scaffold Thrombosis BIOSOLVE-II 24-month follow-up Definite/Probable Scaffold Thrombosis BIOSOLVE-III 6-month follow-up Definite/Probable Scaffold Thrombosis 0.0% 0.0% 0.0% 1) BIOSOLVE-I data from Haude M. et al., EuroIntervention 2016;12:e160-e166 2) BIOSOLVE-II data from Haude M., oral abstract presentation, EuroPCR ) BIOSOLVE-III data from Haude M., oral abstract presentation, EuroPCR 2017
5 Scaffold Thrombosis Factors Stent geometry Stent geometry Late-aquired incomplete device apposition Delayed or incomplete endothelialisation of device struts Hypersensitivity or inflammatory reactions to device components Modified from : Capodanno D, et al., EuroIntervention, 2015;11 Suppl V:V181-4
6 Scaffold Thrombosis Factors Stent geometry Stent geometry Late-aquired incomplete device apposition Delayed or incomplete endothelialisation of device struts Hypersensitivity or inflammatory reactions to device components Modified from : Capodanno D, et al., EuroIntervention, 2015;11 Suppl V:V181-4
7 Computed flow dynamics aims to explain how strut thickness may influence device thrombogenicity Greater strut thickness is associated with increased platelet activation due to higher shear stress. In addition, platelet aggregation is increased due to larger areas of regional flow reverse and stasis. 1) 2) 3) 1) Foin, N., et al. IJCA. 2014;143 (09), 2) Tolentino, A. Cardiov.Nurse/Tech. Symp. 2016, 3) Koskinas K., J Am Coll Cardiol Apr 10;59(15):
8 Computed flow dynamics suggest accelerated endothelialization in relative to Absorb The backbone design was found to optimize the wall shear stress compared to the Absorb design. High WSS in between strut crowns (green areas) is physiologic and is associated with accelerated endothelialization. low high Absorb IIB(R)03_2017_Entwurf BIOTRONIK data on file
9 Evaluation of acute thrombogenicity in a well established porcine arteriovenous shunt model Stent geometry, coating and backbone composition impact on acute thrombogenicity Thicker stent struts show greater thrombus deposition as compared with thinner stent struts
10 Evaluation of acute thrombogenicity in vs. Absorb vs. Orsiro Shunt study 1: Comparison of acute thrombogenicity of Absorb vs vs. Orsiro Detection of platelets and inflammatory cells by immunofluorescence Estimation of thrombus deposition by SEM Shunt model AV-shunt with a sylgard tube (inner diameter 2.70mm) 1h blood flow or until >50% reduction of blood flow Target blood activated clotting times (ACT) were kept between s by i.v. Administration of heparin (low heparin model) No antiplatelet agents (e.g. Aspirin, clopidogrel) were used Otsuka et al., JACC Cardiovasc Interv Aug 17;8(9): Waksman R. et al., In press Circulation Intervention
11 Results Shunt Study 1: vs. Absorb vs. Orsiro Shunt study 1: Comparison of acute thrombogenicity of Absorb vs Orsiro and Detection of platelets and inflammatory cells by immunofluorescence Estimation of thrombus deposition by SEM Absorb Orsiro Photo SEM IF Waksman R. et al., In press Circulation Cardiovascular Intervention
12 Results Shunt Study 1: vs. Absorb vs. Orsiro Scanning Electron Microscopy Significantly less thrombus deposition in compared to Absorb Less inflammatory cells in compared to Absorb Arrows: thrombus deposition, arrowhed: inflammatory cells Waksman R. et al., In press Circulation Cardiovascular Intervention
13 Results Shunt Study 1: vs. Absorb vs. Orsiro Immunoflurescence Significantly less platelet coverage in and Orsiro compared to Absorb Waksman R. et al., In press Circulation Cardiovascular Intervention
14 Evaluation of acute thrombogenicity in vs. 316L-Equivalent Shunt study 2: Effect of magnesium backbone on acute thrombogenicity of vs scaffold design in stainless steel (316L-equivalent): Detection of platelets and inflammatory cells by immunofluorescence Estimation of thrombus deposition by SEM Shunt model AV-shunt with a sylgard tube (inner diameter 2.70mm) 1h blood flow or until >50% reduction of blood flow Target blood activated clotting times (ACT) were kept between s by i.v. Administration of heparin (low heparin model) No antiplatelet agents (e.g. Aspirin, clopidogrel) were used Otsuka et al., JACC Cardiovasc Interv Aug 17;8(9): Waksman R. et al., In press Circulation Intervention
15 Results Shunt Study 2: vs 316L-Equivalent Shunt study 2: Effect of magnesium backbone on acute thrombogenicity of vs 316L- Equivalent: Detection of platelets and inflammatory cells by immunofluorescence Estimation of thrombus deposition by SEM 316L-Equivalent Photo SEM IF
16 Results Shunt Study 2: vs 316L-Equivalent Scanning Electron Microscopy Significantly less thrombus deposition in compared to 316L-Equivalent Less inflammatory cells in SEM 316L-Equivalent Arrows: thrombus deposition, arrowhed: inflammatory cells
17 Results Shunt Study 2: vs 316L-Equivalent Immunofluorescence Significantly less platelet coverage in compared to stainless steel P< stainless steel 316L-Equivalent
18 Scaffold Thrombosis Factors Stent geometry Stent geometry Late-aquired incomplete device apposition Delayed or incomplete endothelialisation of device struts Hypersensitivity or inflammatory reactions to device components Modified from : Capodanno D, et al., EuroIntervention, 2015;11 Suppl V:V181-4
19 Computed flow dynamics aims to explain how late recoil may cause malapposition which in turn may influence device thrombogenicity 1 Absorb Absorb showed no recoil increase, whereas Absorb diameter decreased >20% within 1st hour in a bench test. 1 Therefore, the polymeric scaffold struts are less apposed to the vessel wall which causes disturbances in the laminar blood flow. 2,3,4 Disturbances activate platelets which play an important role of the thrombus formation cascade. 2 The impact of recoil on the laminar blood flow was simulated using computational flow dynamics. 1) Schmidt W et al. In vitro performance investigation of bioresorbable scaffolds - Standard tests for vascular stents and beyond.cardiovascular Revascularization Medicine. 2016; 17(6): ) Foin N et al. Incomplete Stent Apposition Causes High Shear Flow Disturbances and Delay in Neointimal Coverage as a Function of Strut to Wall Detachment Distance, DOI: /CIRCINTERVENTIONS ) Kolandaivelu K et al. Stent Thrombogenicicty Early in High-Risk Interventional Settings Is Drive by Stent design and Deployment and Protected by Polymer-Drug Coatings DOI: /CIRCULTATIONAHA ) Jiménez J.M., Davies P.F. Hemodynamically Driven Stent Strut Design. Annals of Biomedical Engineering. 2009
20 Platelet Shear Number (PSN) Computed flow dynamics predicted the impact of recoil on the risk of platelet activation and platelet aggregation Platelet Convection Number (PCN) Platelet Aggregation Number (PAN) was simulated with a stable 5% recoil. Absorb was simulated with a 5% and 8% recoil at acute and 1 hour postimplantation respectively 1. Only the results 1-hour post-implantation are shown here. Computed flow dynamic simulation predicts the lowest risk of platelet activation for and the highest for Absorb. 2 The activated platelets are transported to the vessel wall. The transport is represented by the platelet convection number, which resulted lowest for. 2 Finally, the transported platelets aggregate. The risk of platelet aggregation is lowest for compared to Absorb Absorb 0 Absorb 0 Absorb 1) Schmidt W. et al, Cardiovasc Revasc Med 2016;17(6): ) IIB(R)03_2017_Entwurf BIOTRONIK data on file, 3) Pictures from:
21 Scaffold Thrombosis Factors Stent geometry Stent geometry Late-aquired incomplete device apposition Delayed or incomplete endothelialisation of device struts Hypersensitivity or inflammatory reactions to device components Modified from : Capodanno D, et al., EuroIntervention, 2015;11 Suppl V:V181-4
22 vs Absorb endothelialisation in rabbit model at 28 days Vessel surface coverage of BRS struts determines pace of re-endothelialisation PLLA BRS p<0.004 p = PLLA BRS Waksman R. et al., EuroIntervention 2017; published online ahead of print
23 Scaffold Thrombosis Factors Stent geometry Stent geometry Late-aquired incomplete device apposition Delayed or incomplete endothelialisation of device struts Hypersensitivity or inflammatory reactions to device components Modified from : Capodanno D, et al., EuroIntervention, 2015;11 Suppl V:V181-4
24 Results Shunt Study 1: vs. Absorb vs. Orsiro Immunoflurescence (2) Significantly less Neutrophil (PM1 + ) adherence in and Orsiro compared to Absorb Significantly less Monocyte (CD14 + ) adherence in compared to Absorb PM1+ Neutrophil staining: green, CD14+ Monocyte staining: green, DAPI nuclei staining: blue, CD42b/CD61 platelelt staining: red Waksman R. et al., In press Circulation Cardiovascular Intervention
25 Results Shunt Study 2: vs 316L-Equivalent Immunofluorescence Neutrophil Attachment Significantly less Neutrophil (PM1 + ) adherence in compared to 316L-Equivalent P< L-Equivalent 316L-Equivalent
26 Results Shunt Study 2: vs 316L-Equivalent Immunofluorescence Monocyte Attachment Significantly less Monocyte (CD14 + ) adherence in compared to 316L-Equivalent P< L-Equivalent 316L-Equivalent
27 Conclusions Geometric design of impacts favorably on acute thrombogenicity relative to Absorb and Orsiro Endothelialization is advanced in relative to Absorb in a rabbit model at 28 days hemodynamic flow properties and biocompatible coating seem to have favorable effects on platelet aggregation and endothelialisation 1 Decreased inflammatory cell attachment in relative to Absorb and Orsiro is observed 1 hour following AV shunt flow The BIOlute coating showed reproducible hemocompatibility on various designs The backbone Magnesium material seems to have a beneficial effect on acute thrombosis risk 1) Malek A.M. et al., Hemodynamic sheer stress and its role in atherosclerosis, JAMA 1999;282:
Bioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
More informationBioresorbable Scaffolds Moving Forward or Backwards?
Bioresorbable Scaffolds Moving Forward or Backwards? George D. Dangas, MD, FACC, MSCAI Professor of Cardiology & Vascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure Statement
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationBioresorbable Stents: Innovation or Bust?
Bioresorbable Stents: Innovation or Bust? Rajiv Jauhar, MD FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital San Diego July, 2016 Conflict of Interest Disclosure
More informationProspective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results
Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results Stefan Verheye, MD PHD ZNA Middelheim Antwerp, Belgium Potential
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationDual-therapy stent technology for patients with coronary artery disease Kalkman, D.N.
UvA-DARE (Digital Academic Repository) Dual-therapy stent technology for patients with coronary artery disease Kalkman, D.N. Link to publication Citation for published version (APA): Kalkman, D. N. (2018).
More informationMagmaris Stent (Biotronik) A Pichard, Ron Waksman. Medstar Washington Hospital Center Washington, DC
Magmaris Stent (Biotronik) A Pichard, Ron Waksman. Medstar Washington Hospital Center Washington, DC Conflict of Interest None for this presentation Downside of Metallic Stents 1. Restenosis No longer
More informationINTERVENTIONAL CARDIOLOGY Bioresorbable Stents Update: Similarities. Generation BVS
INTERVENTIONAL CARDIOLOGY 2017 32 ND ANNUAL INTERNATIONAL SYMPOSIUM Bioresorbable Stents Update: Similarities and Differences in Comparison to First Generation BVS Dariusz Dudek Institute of Cardiology
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationHow to Predict & Prevent It! George D. Dangas, MD, FACC, FESC
Stent Thrombosis How to Predict & Prevent It! George D. Dangas, MD, FACC, FESC Professor of Cardiology & Vascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Καθηγητής Καρδιολογίας ΕΚΠΑ
More informationAffiliation/Financial Relationship
The Next ERA: COMBO Dual Therapy Stent The Unmet Need Roxana Mehran, MD Mount Sinai i School of Medicine i Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationCoronary Stents: Past, Present, Future
Coronary Stents: Past, Present, Future Michael C Kim, MD FACC Director Cath Lab and IC Lenox Hill Heart and Vascular Institute Northwell Health IC-296208-AN DEC 2016 Page 1 1st-Generation DES was not ideal
More informationΒιοαποδομήσιμα Στεφανιαία Ικριώματα με βάση το μαγνήσιο. Magnesium Bioresorbable Coronary Scaffolds
Βιοαποδομήσιμα Στεφανιαία Ικριώματα με βάση το μαγνήσιο. Magnesium Bioresorbable Coronary Scaffolds Βάιος Π. Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Ερρίκος Ντυνάν HC Δεν υπάρχει σύγκρουση συμφερόντων
More informationNext Generation Drug- eluting Stent : Will It Solve the Problem?
Next Generation Drug- eluting Stent : Will It Solve the Problem? Yangsoo Jang, M.D., Ph.D, FACC Severance Cardiovascular Hospital Yonsei University Healthcare System Commercially Available DES An Epidemic
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationΝεότερα DES stents. Δεδοµένα εφαρµογής των και προοπτικές
Νεότερα DES stents. Δεδοµένα εφαρµογής των και προοπτικές Δηµήτρης Γ. Σιώνης Αιµοδυναµικό Τµήµα Επεµβατικής Καρδιολογίας Σισµανόγλειο-Αµ. Φλέµιγκ ΓΝ Αθήνα Δήλωση συµφερόντων None for the presentation Potential
More informationThe role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium
The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium Disclosures Speaker name: Frank Vermassen I have the following potential
More informationΕνδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ
Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ DES Penetration -(2011) Source: Millenium Research Group Cordis has stopped manufacturing
More informationThe titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath
The titanium nitride oxide stent an alternative to DES Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath Advanced Angioplasty 2008 Declaration of interest I have received an honorarium
More informationBéla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment
Semmelweis University Heart Center Budapest, Hungary Béla MERKELY MD, PhD, DSc, FESC Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment 10th Interventional
More informationCONTEMPORARY DRUG-ELUTING STENTS AND VASCULAR RESPONSE
CONTEMPORARY DRUG-ELUTING STENTS AND VASCULAR RESPONSE Anwer Habib, 1 Hiroyoshi Mori, 2 Kazuyuki Yahagi, 2 *Aloke V. Finn 2,3 1. Parkview Heart Institute, Fort Wayne, Indiana, USA 2. CVPath Institute Inc.,
More informationStents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.
Stents selection and optimal implantation: sizes, design, deployment Stent classification: Mechanism of expansion - Self-expanding - Balloon expandable Design - Mesh structure - Coil - Slotted tube - Ring
More informationBIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions
BIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions Johannes Waltenberger, MD, F.E.S.C. Uniklinik Münster Münster, Germany
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More informationΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ
ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ Νίκος Μεζίλης MD, FESC Κλινική Άγιος Λουκάς Why diabetes is associated with restenosis endothelial dysfunction metabolic alterations accelerated platelet deposition
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationDevelopment of Computational Models for Evaluation of Mechanical and Hemodynamic Behavior of an Intravascular Stent
Development of Computational Models for Evaluation of Mechanical and Hemodynamic Behavior of an Intravascular Stent Kuang-Huei Lee, Hao-Ming Hsiao, Ying-Chih Liao, Yi-Hsiang Chiu, Yu-Seng Tee Dept. of
More informationReduction in Stent Thrombosis better tablets or better stents?
Reduction in Stent Thrombosis better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton MY CONFLICTS OF INTEREST ARE Speaker Fees/Honoraria/Travel Support Lilly/Daiichi
More informationInsights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up
Insights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up Ron Waksman, MD FACC FSCAI FESC Professor of Medicine, Georgetown University Director, Cardiovascular Research
More informationABT 578 Elution from Phosphorylcholine: Zomaxx (Abbott)
ABT 578 Elution from Phosphorylcholine: Zomaxx (Abbott) Alan Yeung, MD Professor of Medicine, Interventional Cardiology Chair, Chief, Division of Cardiovascular Medicine (Clinical) Stanford University
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationContinuing Cardiology Education
Continuing Cardiology Education Stent selection for percutaneous coronary intervention P. D. Williams* & M. Awan James Cook University Hospital, Middlesbrough, United Kingdom Keywords Coronary artery disease,
More informationWill Bioresorbable Scaffolds Change How We Think About Left Main PCI?
TCT 2014 13 Sep 2014-17 Sep 2014, Washington, DC - U.S.A Will Bioresorbable Scaffolds Change How We Think About Left Main PCI? Robert-Jan van Geuns, MD, PhD Professor of Interventional Cardiology, Thoraxcenter,
More informationChallenges of in-stent Restenosis. The Balloon Approach
Challenges of in-stent Restenosis The Balloon Approach Bruno Scheller Klinische und Experimentelle Interventionelle Kardiologie, Universität des Saarlandes, Campus Homburg Klinik für Innere Medizin III,
More information2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES
2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES Marlies M. Kok, MD Thoraxcentrum Twente, MST, Enschede, the Netherlands On behalf of the BIO-RESORT
More informationMedical Product Development: Commercial Success Extends Beyond Regulatory Approval James P. Oberhauser, Ph.D.
Medical Product Development: Commercial Success Extends Beyond Regulatory Approval James P. Oberhauser, Ph.D. Associate Director, Device Development and Clinical Packaging Engineering Gilead Sciences,
More informationBoston Scientific Corporation Drug-Eluting Stent Program
Boston Scientific Corporation Drug-Eluting Stent Program Copyright 2002 by Scimed Life Systems, Inc. All rights reserved. Program Overview λ λ λ λ λ World Wide Status Restenosis Paclitaxel Polymers Dose
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationInterventional Cardiology
Interventional Cardiology Volume 6 Issue 2 Extract Orsiro The First Hybrid Drugeluting Stent, Opening Up a New Class of Drug-eluting Stents for Superior Patient Outcomes Michael Tittelbach 1 and Tobias
More informationBioabsorbable Scaffolds - the future, Jacques Koolen
Bioabsorbable Scaffolds - the future, a passing fad or somewhere in between? Jacques Koolen Amsterdam POBA Acute closure Restenosis 3 months 30-50% BMS DES First generation Subacute-late trombus very
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationResolute Integrity. Independent Conformability Assessment
Resolute Integrity Independent Conformability Assessment Stent Conformability and its Clinical Importance Immediate post-deployment stent geometry determines neointimal thickness independently of arterial
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationBIOABSORBABLE DEVICES IN CONGENITAL HEART DISEASE
BIOABSORBABLE DEVICES IN CONGENITAL HEART DISEASE John P. Breinholt, M.D., FACC, FSCAI Riley Hospital for Children Indiana University School of Medicine DISCLOSURES Abbott Vascular Investigator Sponsored
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST In the last five years, I received research grants or speaker fees or I am/was consultant for: Abbott Vascular, Asahi, Astra Zeneca, AVI, Boston Scientific, Biotronik,
More informationDISAPPEARING STENT: IS THE TIME APPEARED?
DISAPPEARING STENT: IS THE TIME APPEARED? Carlo Cernetti Chief Cardiology Division San Giacomo Hospital Castelfranco Veneto (TV) 1 THE BEGINNING START randomized study (n=452) Long-term follow-up The benefit
More informationBioresorbable scaffolds versus metallic stents in routine PCI: the plot thickens
Editorial Bioresorbable scaffolds versus metallic stents in routine PCI: the plot thickens Athanasios Katsikis 1, Patrick W. Serruys 2 1 401 General Military Hospital of Athens, Cardiology Department,
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationOCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?
OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research
More informationSTENT OR SCAFFOLD THROMBOSIS: PAST, CURRENT, AND FUTURE PERSPECTIVES
STENT OR SCAFFOLD THROMBOSIS: PAST, CURRENT, AND FUTURE PERSPECTIVES Hideki Wada, 1 Peter C. Mattson, 2 *Hiroshi Iwata 1 1. Department of Cardiovascular Medicine, Juntendo University Graduate School of
More informationBIOFLOW V Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents
Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents David E Kandzari, MD; Laura Mauri, MD, MSc; Jacques Koolen, MD, PhD; Joseph M Massaro,
More informationMulticenter Clinical Trial on the Impact of Biomechanical Factors on Bifurcation Stent Restenosis and Thrombosis
11th EBC, Athens, Greece September 25 & 26, 2015 Multicenter Clinical Trial on the Impact of Biomechanical Factors on Bifurcation Stent Restenosis and Thrombosis Yiannis S. Chatzizisis, MD, PhD Associate
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent Bernard Chevalier
More informationBIOFLOW by Orsiro stents
BIOFLOW by stents Byeong-Keuk Kim, MD, PhD Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine Key Benefits Clinically proven
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationActa Cardiol Sin 2018;34: doi: /ACS _34(2) A
Original Article Acta Cardiol Sin 2018;34:124 129 doi: 10.6515/ACS.201803_34(2).20171115A Coronary Artery Disease Vascular Healing Response after Everolimus-Eluting Stent Implantation in Acute Coronary
More informationSTENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
More informationEberhard Grube MD FSCAI, FACC
SCAI 30 th Annual Scientific Sessions Orlando/Fla BMS and DES Thrombosis Differences among DES Eberhard Grube MD FSCAI, FACC HELIOS Heart Center Siegburg, Siegburg, Germany Stanford University, School
More informationThe Latest Experimental Results of Endothelialization with BuMA stent. Renu Virmani, MD CVPath Institute, Inc. Gaithersburg, Maryland, USA
The Latest Experimental Results of Endothelialization with BuMA stent Renu Virmani, MD CVPath Institute, Inc. Gaithersburg, Maryland, USA In Stent Re -stenosis [%] Neointimal Thickness [mm] A Great Success
More informationMechanical behavior of polymer-based vs. metallic-based bioresorbable stents
Review Article Mechanical behavior of polymer-based vs. metallic-based bioresorbable stents Hui Ying Ang 1, Ying Ying Huang 2, Soo Teik Lim 1,3, Philip Wong 1,3, Michael Joner 4, Nicolas Foin 1 1 National
More informationStent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study
DOI 10.1007/s10554-012-0032-6 ORIGINAL PAPER Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study Tuomas Lehtinen
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationLATE AND VERY LATE STENT THROMBOSIS IN THE ERA OF SECOND-GENERATION DRUG-ELUTING STENTS
LATE AND VERY LATE STENT THROMBOSIS IN THE ERA OF SECOND-GENERATION DRUG-ELUTING STENTS Jaya Mallidi, *Amir Lotfi Division of Cardiology, Baystate Medical Center, Tufts University, Springfield, Massachusetts,
More informationCLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus
CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus OPTICAL COHERENCE TOMOGRAPHY (OCT) IVUS and OCT IVUS OCT
More informationInterventional cardiology has made great strides in
STEPHEN G. ELLIS, MD Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic HARIS RIAZ, MD Resident, Department of Internal Medicine, Cleveland Clinic Bioresorbable stents:
More informationVascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts
Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience
More informationCoronary Stents: Past, Present and Future
Kardiologie Kardio Lunch 07.04.2016 Coronary Stents: Past, Present and Future Christoph Kaiser Universitätsspital Basel Rubin GS, The first balloon-expandable coronary stent, University of Queensland Press
More informationBTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration
BTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration M Sapoval, C Del Giudice, C Dean Interventional Radiology Dep Hôpital Européen Georges Pompidou APHP, Paris, France IMPORTANT
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the Everolimus Eluting Stent Bernard Chevalier
More informationThe need for mechanical support for dilated vessels
Implantation Technique for Bioresorbable Scaffolds Device description and patient/lesion selection with the Absorb BVS. BY JIANG MING FAM, MD, MBBS, AND ROBERT-JAN van GEUNS, MD, PhD, FESC, FACC The need
More informationShedding light on stent thrombosis
Editorial Shedding light on stent thrombosis Tawfiq Choudhury 1,2, Rodrigo Bagur 1,2, Ashlay A. Huitema 1,2, Amir Solomonica 1,2, Shahar Lavi 1,2 1 Department of Medicine, Western University, London, ON,
More informationBioabsorbable Scaffolds: The Next Holy Grail?
Bioabsorbable Scaffolds: The Next Holy Grail? New Cardiovascular Horizons New Orleans, LA June 06, 2013 Lewis B. Schwartz, M.D., F.A.C.S. Vascular Surgery and Endovascular Therapy University of Chicago
More informationProven Performance Through Innovative Design *
Proven Performance Through Innovative Design * Deliver Our Next Generation AV Covered Stent Results The COVERA Vascular Covered Stent builds upon proven technologies from the category leader in AV Access.
More informationLeft main coronary artery (LMCA): The proximal segment
Anatomy and Pathology of Left main coronary artery G Nakazawa Tokai Univ. Kanagawa, Japan 1 Anatomy Difinition Left main coronary artery (LMCA): The proximal segment RCA AV LAD LM LCX of the left coronary
More informationA Highly Flexible Slotted Tube Stent Design Coated with a-sic:h First Clinical Experiences
40 February 1998 A Highly Flexible Slotted Tube Stent Design Coated with a-sic:h First Clinical Experiences J. KOOLEN, C. HANEKAMP, H. BONNIER 1Catharina Hospital, Eindhoven, Netherlands Summary A new
More informationXIENCE Sierra INTRODUCING
INTRODUCING Sierra With the safety you ve always relied on and the deliverability you ve always wanted, choosing the right stent is now an easier decision. START 2017 Abbott. All rights reserved. AP2944678-OUS
More informationASX Small to Mid Caps New York Conference. March 1, 2012
ASX Small to Mid Caps New York Conference March 1, 2012 Important Notice Not an Offer for Securities This presentation has been prepared by REVA Medical, Inc. (REVA or the Company) solely for its use at
More information生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所
生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所 PCI milestones Pre Post Biodegradable polymer? 1 st revolution 1977 PTCA 2 nd revolution 1988 BMS 3 rd revolution 2000 DES Bioresorbable
More informationDauer der doppelten Plättchenhemmung nach AMI / Stent
Dauer der doppelten Plättchenhemmung nach AMI / Stent Kardio-Lunch 04.06.2014 Christoph Kaiser Universitätsspital Basel Christoph.kaiser@usb.ch DAPT after Stenting 257 patients with PCI & stent: ASS &
More informationBioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland Disclosures I am not Ron Waksman 1 Clinical experience with AMS
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationFreedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK
Freedom to Treat Your High Bleeding Risk Patients Tim Kinnaird University Hospital of Wales, Cardiff, UK Relevant Disclosures Honoraria for lectures from: o Eli Lilly & Co, Daiichi Sankyo, Boehringer,
More informationClinically proven. ordering info. Vascular Intervention // Peripheral Self-Expanding Stent System/0.018 /OTW. Pulsar-18
140 μm thin struts Clinically proven 4F low profile Vascular Intervention // Peripheral Self-Expanding Stent System/0.018 /OTW Pulsar-18 Technical data / ordering info 140 μm thin struts - thinner than
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationHow far have we come with bioresorbable vascular scaffolds, and where should we go?
Editorial How far have we come with bioresorbable vascular scaffolds, and where should we go? Jeehoon Kang, Kyung Woo Park, Hyo Soo Kim Department of Internal Medicine and Cardiovascular Center, Seoul
More informationEvaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study
Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study OrbusNeich Dual Therapy COMBO Stent Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM FACC
More informationOptical Coherence Tomography
Optical Coherence Tomography Disclosure Information Demetrius Lopes MD The following relationships exist related to this presentation: University Grant/Research Support: Rush University Industry Grant
More informationCOMPLEX CASES: LEFT MAIN
COMPLEX CASES: LEFT MAIN Resolute Onyx DES Together are trademarks of Medtronic. * Third-party brands are trademarks of For distribution only in markets where the Resolute Onyx coronary stent has been
More informationPercutaneous Coronary Intervention: an Update for the Internist
Percutaneous Coronary Intervention: an Update for the Internist Michael W. Cammarata, MD, MS Boca Raton Reginal Hospital Grand Rounds January, 9 2018 Objectives/Outline Background/Introduction Patient
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More information2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More information